TY - JOUR
T1 - The Last 10 Days of Patients With Glioblastoma
T2 - Assessment of Clinical Signs and Symptoms as well as Treatment
AU - Thier, Katrin
AU - Calabek, Bernadette
AU - Tinchon, Alexander
AU - Grisold, Wolfgang
AU - Oberndorfer, Stefan
N1 - Publisher Copyright:
© 2015, © The Author(s) 2015.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - BACKGROUND: High-grade gliomas are the most frequent primary brain tumors. Despite improvement in diagnostics and treatment, survival is still poor and quality-of-life issues are of major importance. Little is known regarding the clinical signs and symptoms of dying patients with glioblastoma.OBJECTIVE: The aim of this study was to investigate signs and symptoms as well as therapeutic strategies in patients with glioblastoma in the end-of-life phase in order to improve end-of-life care.METHODS: In this prospective single-center study, clinical data were obtained using a standardized protocol. We descriptively analyzed signs, symptoms, and therapeutic strategies on a daily basis.RESULTS: A total of 57 patients, who died due to glioblastoma in a hospital setting, were included. The most frequent signs and symptoms in the last 10 days before death were decrease in level of consciousness (95%), fever (88%), dysphagia (65%), seizures (65%), and headache (33%). Concerning medication, 95% received opioids. There was a high need for nonsteroidal anti-inflammatory drugs (77%) and anticonvulsants (75%). Steroids were given to 56%.CONCLUSION: Due to a decrease in level of consciousness and cognitive impairment, assessment of clinical signs and symptoms such as headache at the end of life is difficult. Based on the signs and symptoms in the last days before death in patients with glioblastoma, supportive drug treatment remains challenging. Our study emphasizes the importance of standardized guidelines for end-of-life care in patients with glioblastoma.
AB - BACKGROUND: High-grade gliomas are the most frequent primary brain tumors. Despite improvement in diagnostics and treatment, survival is still poor and quality-of-life issues are of major importance. Little is known regarding the clinical signs and symptoms of dying patients with glioblastoma.OBJECTIVE: The aim of this study was to investigate signs and symptoms as well as therapeutic strategies in patients with glioblastoma in the end-of-life phase in order to improve end-of-life care.METHODS: In this prospective single-center study, clinical data were obtained using a standardized protocol. We descriptively analyzed signs, symptoms, and therapeutic strategies on a daily basis.RESULTS: A total of 57 patients, who died due to glioblastoma in a hospital setting, were included. The most frequent signs and symptoms in the last 10 days before death were decrease in level of consciousness (95%), fever (88%), dysphagia (65%), seizures (65%), and headache (33%). Concerning medication, 95% received opioids. There was a high need for nonsteroidal anti-inflammatory drugs (77%) and anticonvulsants (75%). Steroids were given to 56%.CONCLUSION: Due to a decrease in level of consciousness and cognitive impairment, assessment of clinical signs and symptoms such as headache at the end of life is difficult. Based on the signs and symptoms in the last days before death in patients with glioblastoma, supportive drug treatment remains challenging. Our study emphasizes the importance of standardized guidelines for end-of-life care in patients with glioblastoma.
KW - Adrenal Cortex Hormones/administration & dosage
KW - Aged
KW - Analgesics, Opioid/administration & dosage
KW - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage
KW - Anticonvulsants/administration & dosage
KW - Brain Neoplasms/complications
KW - Deglutition Disorders/etiology
KW - Female
KW - Fever/drug therapy
KW - Fluid Therapy
KW - Glioblastoma/complications
KW - Humans
KW - Male
KW - Middle Aged
KW - Palliative Care/methods
KW - Prospective Studies
KW - Quality of Life
KW - Seizures/drug therapy
KW - Terminal Care/methods
KW - Unconsciousness/etiology
KW - Vital Signs
UR - http://www.scopus.com/inward/record.url?scp=84994071402&partnerID=8YFLogxK
U2 - 10.1177/1049909115609295
DO - 10.1177/1049909115609295
M3 - Journal article
C2 - 26472939
SN - 1049-9091
VL - 33
SP - 985
EP - 988
JO - American Journal of Hospice and Palliative Medicine
JF - American Journal of Hospice and Palliative Medicine
IS - 10
ER -